Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: A cohort study of patients registered in the Danish biologics registry

Rheumatology (United Kingdom)

Volumn 54, Issue 12, 2015, Pages 2156-2165

  Jørgensen, Tanja Schjødt ^a   Kristensen, Lars Erik ^a,b   Christensen, Robin ^a   Bliddal, Henning ^a   Lorenzen, Tove ^c   Hansen, Michael S ^d   Østergaard, Mikkel ^e   Jensen, Jørgen ^f   Zanjani, Lida ^e   Laursen, Toke ^g   Butt, Sheraz ^a   Dam, Mette Y ^h   Lindegaard, Hanne M ⁱ   Espesen, Jakob ^j   Hendricks, Oliver ^k   Kumar, Prabhat ^l   Kincses, Anita ^m   Larsen, Line H ⁿ   Andersen, Marlene ^o   Næser, Esben K ^c   Jensen, Dorte V ^g   Grydehøj, Jolanta ^p   Unger, Barbara ^q   Dufour, Ninna ^r   Sørensen, Vibeke ^s   Vildhøj, Sara ^t   Hansen, Inger Marie Jensen ⁱ   Raun, Johnny ^j   Krogh, Niels Steen ^d   Hetland, Merete Lund ^e,u   more..

^a Mental Health Center Glostrup   (Denmark)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c SILKEBORG REGIONAL HOSPITAL   (Denmark)

^d ReumaKlinik Roskilde ^*  (Denmark)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^f Region Hospital Køge   (Denmark)

^g GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ ODENSE UNIVERSITY HOSPITAL   (Denmark)

^j LILLEBAELT HOSPITAL   (Denmark)

^k King Christian the Xth Hospital   (Denmark)

^l ESBJERG HOSPITAL   (Denmark)

^m Rigshospitalet   (Denmark)

ⁿ AALBORG UNIVERSITY HOSPITAL   (Denmark)

^o NORTH DENMARK REGIONAL HOSPITAL   (Denmark)

^p VIBORG HOSPITAL   (Denmark)

^q HORSENS REGIONAL HOSPITAL   (Denmark)

^r Nordsjællands Hospital Hillerød   (Denmark)

^s RANDERS REGIONAL HOSPITAL   (Denmark)

^t HOLSTEBRO HOSPITAL   (Denmark)

^u UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

Biologics; Cohort study; DMARDs; Monotherapy; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DENMARK; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; PATIENT CARE; PATIENT COMPLIANCE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REGISTER; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

EID: 84983127766     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev216     Document Type: Article

References (28)

1. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
2. Singh JA, Furst DE, Bharat A et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.
3. Nam JL, Ramiro S, Gaujoux-Viala C et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73:516-28.
4. Furst DE, Keystone EC, Braun J et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012;71 (Suppl 2):i2-45.
5. Yazici Y, Shi N, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16, 752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis 2008;66:77-85.
6. Hetland ML, Lindegaard HM, Hansen A et al. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2008;67:1023-6.
7. Christensen R, Bliddal H, Henriksen M. Enhancing the reporting and transparency of rheumatology research: a guide to reporting guidelines. Arthritis Res Ther 2013;15:109.
8. Vandenbroucke JP, von EE, Altman DG et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007;147:W163-94.
9. Dixon WG, Carmona L, Finckh A et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis 2010;69:1596-602.
10. Hetland ML. DANBIO-powerful research database and electronic patient record. Rheumatology 2011;50:69-77.
11. Hjardem E, Ostergaard M, Podenphant J et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis 2007;66:1184-9
12. Hetland ML, Christensen IJ, Tarp U et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32.
13. Kay J, Morgacheva O, Messing SP et al. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther 2014;16:R40.
14. Prevoo ML, van't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
15. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a fiveyear observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006;54:600-6.
16. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8:R174.
17. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
18. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
19. van der HD, Klareskog L, Rodriguez-Valverde V et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: twoyear clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74.
20. Keystone EC, Genovese MC, Klareskog L et al. Golimumab, a human antibody to tumour necrosis factor (alpha) given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.
21. Fleischmann R, Vencovsky J, van Vollenhoven RF et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68:805-11.
22. Leffers HC, Ostergaard M, Glintborg B et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011;70:1216-22.
23. Choy EH, Smith C, Dore CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 2005;44:1414-21.
24. Ellegaard K, Christensen R, Torp-Pedersen S et al. Ultrasound Doppler measurements predict success of treatment with anti-TNF-a; drug in patients with rheumatoid arthritis: a prospective cohort study. Rheumatology 2011;50:506-12.
25. Neovius M, Arkema EV, Olsson H et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 2015;74:354-60.
26. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
27. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
28. Askling J, Ernestam S, Forsblad-d'Elia H et al. Which RA patients end up starting which biologic? A nationwide assessment of differential channelling to biologic treatments in Sweden 2006-2011. Ann Rheum Dis 2013;72(Suppl3):455.